New Jersey headquartered Immunomedics Inc.'s stock dropped 4.58%, finishing last Friday's session at $2.29. A total volume of 1.42 million shares was traded, which was above their three months average volume of 1.38 million shares. The Company's shares are trading below their 200-day moving average by 18.27%. Additionally, shares of Immunomedics, which focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases, have a Relative Strength Index (RSI) of 28.01.
On October 06th, 2016, research firm Jefferies resumed its 'Buy' rating on the Company's stock.
On October 12th, 2016, Immunomedics announced that it has closed on a previously disclosed underwritten offering of 10,000,000 shares of common stock and warrants to purchase up to 10,000,000 shares of common stock, with gross proceeds of $30 million. Each share of common stock and its accompanying warrant was priced at $3.00. Immunomedics intends to use the proceeds from the offering primarily in continuing support of clinical and regulatory activities for IMMU-132, including submission of a NDA to FDA for accelerated approval in metastatic triple-negative breast cancer, and for working capital and general corporate purposes. Your complete research report on IMMU can be retrieved for free at:
On Friday, shares in Waltham, Massachusetts headquartered ImmunoGen Inc. ended the session 5.81%, lower at $2.27. The stock recorded a trading volume of 1.97 million shares, which was above its three months average volume of 1.20 million shares. The Company's shares are trading below their 50-day moving average by 19.91%. Moreover, shares of ImmunoGen, which develops targeted anticancer therapeutics, have an RSI of 26.93.
On September 29th, 2016, ImmunoGen announced the completion of a strategic review of its operations. As a result of this initiative, the Company will reduce its workforce by 17% and seek to partner its non-core B-cell lymphoma programs, creating a stronger organization focused on delivering innovative ADC therapies that meaningfully improve the lives of cancer patients. IMGN free report is just a click away at:
Chandler, Arizona headquartered INSYS Therapeutics Inc.'s stock fell 6.36%, to close the day at $11.05, with a total trading volume of 719,353 shares. Shares of the Company, which develops and commercializes supportive care products, are trading 24.52% below their 50-day moving average. The stock has an RSI of 31.48.
On September 22nd, 2016, research firm RBC Capital Markets reiterated its 'Outperform' rating on the Company's stock with a decrease of the target price from $32 a share to $26 a share.
On October 13th, 2016, Insys Therapeutics announced that its preliminary estimated revenues from Subsys® for Q3 2016 will be in the range of $54 million to $55 million. The Company believes it will be cash-flow positive at this level of sales and will be able to meet its overall objectives of new product development and future growth. Estimated revenues for the quarter reflect a decline in prescriptions as the Company continues to believe that the ongoing and heightened publicity surrounding the national opioid epidemic and continuing governmental and regulatory scrutiny of the Company and the transmucosal immediate release fentanyl ("TIRF") class has resulted in a sensitivity by some healthcare providers to prescribe and dispense TIRF medications. Sign up for your complimentary research report on INSY at:
Shares in Ireland headquartered Jazz Pharmaceuticals PLC recorded a trading volume of 302,168 shares, and ended Friday's session at $118.34, down 2.30%. The stock is trading below its 50-day moving average by 8.05%. Shares of the Company, which identifies, develops, and commercializes pharmaceutical products for various medical needs in the US, Europe, and internationally, have an RSI of 35.56.
On October 03rd, 2016, Jazz Pharma announced the initiation of a rolling submission of a New Drug Application (NDA) to the U.S. FDA on September 30th, 2016, seeking marketing approval of Vyxeos™, an investigational agent for the treatment of acute myeloid leukemia (AML). The company expects to complete the submission of the NDA by early 2017, and will request a priority review. Vyxeos was granted Breakthrough Therapy Designation in May 2016 for the treatment of adults with therapy-related AML or AML with myelodysplasia-related changes. Register for free on Stock-Callers.com and download the latest research report on JAZZ at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA